An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma

Inclusion Criteria:

1. Age range from 18 to 70 years old;
2. Expected survival time\>12 weeks;
3. Diagnosed as multiple myeloma through physical examination, pathological examination, laboratory examination, and imaging;
4. Difficult to treat multiple myeloma patients;
5. Patients with recurrent multiple myeloma;
6. ALT, AST\<3 times normal; Bilirubin\<2.0mg/dl;
7. Quality of Life Score (KPS)\>50%;
8. The patient has no serious diseases such as heart, liver, or kidney;
9. Recurrence or no remission of the disease after hematopoietic stem cell transplantation or cellular immunotherapy;
10. Inappropriate conditions for stem cell transplantation or abandonment of transplantation due to limitations in conditions;
11. Blood can be taken intravenously without any other contraindications for leukocyte removal surgery;
12. Can understand and voluntarily sign a written informed consent form.

Exclusion Criteria:

1. Pregnant or lactating women, or women with pregnancy plans within six months;
2. Infectious diseases (such as HIV, active tuberculosis, etc.);
3. Active hepatitis B or hepatitis C infection;
4. Feasibility assessment screening proves that the transfection of targeted lymphocytes is less than 10% or the amplification is insufficient (\<5-fold) under the co stimulation of CD3/CD28;
5. Abnormal vital signs and inability to cooperate with the examination;
6. Individuals with mental or psychological disorders who cannot cooperate with treatment and efficacy evaluation;
7. Highly allergic constitution or a history of severe allergies, especially those who are allergic to IL-2;
8. Subjects with systemic or severe local infections requiring anti infection treatment;
9. Subjects with severe autoimmune diseases;
10. The doctor believes that there are other reasons why patients cannot be included in treatment.